Screening for MOG-IgG and 27 other anti-glial and anti-neuronal autoantibodies in ‘pattern II multiple sclerosis’ and brain biopsy findings in a MOG-IgG-positive case

@article{Jarius2016ScreeningFM,
  title={Screening for MOG-IgG and 27 other anti-glial and anti-neuronal autoantibodies in ‘pattern II multiple sclerosis’ and brain biopsy findings in a MOG-IgG-positive case},
  author={Sven Jarius and Imke Metz and Fatima Barbara K{\"o}nig and Klemens Ruprecht and Markus Reindl and Friedemann Paul and Wolfgang Br{\"u}ck and Brigitte Wildemann},
  journal={Multiple Sclerosis Journal},
  year={2016},
  volume={22},
  pages={1541 - 1549}
}
Background: Histopathological studies have revealed four different immunopathological patterns of lesion pathology in early multiple sclerosis (MS). Pattern II MS is characterised by immunoglobulin and complement deposition in addition to T-cell and macrophage infiltration and is more likely to respond to plasma exchange therapy, suggesting a contribution of autoantibodies. Objective: To assess the frequency of anti-myelin oligodendrocyte glycoprotein (MOG), anti-M1-aquaporin-4 (AQP4), anti-M23… 

Figures and Tables from this paper

Comparison of Clinical and Radiological Features of Aquaporin4 (AQP-4) Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD) and Anti Myelin Oligodendrocyte Glycoprotein (Anti-MOG) Syndrome-Our Experience from Northwest India
Background: More and more cases of myelin oligodendrocyte glycoprotein (MOG) antibody are being diagnosed with the availability of laboratory tests helping us to know the differing patterns from
Autoantibodies to MOG in a distinct subgroup of adult multiple sclerosis
TLDR
Antibodies to MOG can be found in a distinct subgroup of adult patients with clinically definite multiple sclerosis with a specific clinical phenotype and may indicate disease heterogeneity.
Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 1: Results from 163 lumbar punctures in 100 adult patients
TLDR
MOG-IgG-positive EM is characterized by CSF features that are distinct from those in multiple sclerosis, important for the differential diagnosis of MS and MOG-EM and add to the understanding of the immunopathogenesis of this newly described autoimmune disease.
Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 2: Results from 108 lumbar punctures in 80 pediatric patients
TLDR
MOG-IgG-associated EM in children is characterized by CSF features that are distinct from those in MS and these findings are important for the differential diagnosis of pediatric MS and MOG-EM and add to the understanding of the immunopathogenesis of this newly described autoimmune disease.
MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: Afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients
TLDR
Retinal neuro-axonal damage and visual impairment after ON in MOG-IgG-positive patients are as severe as in AQP4-IGG- positive NMOSD patients.
Myelin oligodendrocyte glycoprotein antibodies in neurological disease
TLDR
Antibodies against myelin oligodendrocyte glycoprotein (MOG-Abs) that are detectable with cell-based assays are associated with non-MS acquired demyelinating syndromes of the CNS, including the value of detection assays and evidence for antibody pathogenicity and its mechanism.
MOG encephalomyelitis: international recommendations on diagnosis and antibody testing
TLDR
Indications for MOG-IgG testing based on expert consensus are proposed and a list of conditions atypical for Mog-EM (“red flags”) are given that should prompt physicians to challenge a positive Mogenogenetically distinct test result.
MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome
TLDR
The predominantly relapsing and often severe disease course and the short median time to second attack support the use of prophylactic long-term treatments in patients with MOG-IgG-positive ON and/or myelitis; however, treatment failure leading to rapid accumulation of disability was noted in many patients as well as flare-ups after steroid withdrawal.
Anti-Myelin Oligodendrocyte Glycoprotein and Human Leukocyte Antigens as Markers in Pediatric and Adolescent Multiple Sclerosis: on Diagnosis, Clinical Phenotypes, and Therapeutic Responses
TLDR
Recent evidence regarding HLA-genotyping and MOG antibodies—the two most important candidate biomarkers for early-onset MS—as well as their potential application in the diagnosis and treatment of MS are reviewed.
...
...

References

SHOWING 1-10 OF 37 REFERENCES
‘Medusa head ataxia’: the expanding spectrum of Purkinje cell antibodies in autoimmune cerebellar ataxia. Part 2: Anti-PKC-gamma, anti-GluR-delta2, anti-Ca/ARHGAP26 and anti-VGCC
TLDR
A detailed review of the clinical and paraclinical features, oncological, therapeutic and prognostic implications, pathogenetic relevance, and differential laboratory diagnosis of the 12 most common PC autoantibodies (often referred to as ‘Medusa head antibodies’ due their characteristic somatodendritic binding pattern) is provided.
Humoral pattern II multiple sclerosis pathology not associated with neuromyelitis Optica IgG.
TLDR
The NMO-IgG status of a cohort of patients with biopsy-proven early active lesions consistent with MS is reported, indicating a greater likelihood than other forms of MS to respond favorably to plasma exchange therapy.
‘Medusa head ataxia’: the expanding spectrum of Purkinje cell antibodies in autoimmune cerebellar ataxia. Part 1: Anti-mGluR1, anti-Homer-3, anti-Sj/ITPR1 and anti-CARP VIII
TLDR
A detailed review of the clinical and paraclinical features, oncological, therapeutic and prognostic implications, pathogenetic relevance, and differential laboratory diagnosis of the 12 most common PC autoantibodies (often referred to as ‘Medusa-head antibodies’ due to their characteristic somatodendritic binding pattern when tested by immunohistochemistry).
Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders
TLDR
It is shown for the first time that a subset of AQP4-IgG seronegative patients with NMO and HR-NMO exhibit a MOG-IGG mediated immune response, whereas MOG is not a target antigen in cases with an AQP 4-directed humoral immune response.
Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder?
While neuromyelitis optica (NMO) immunoglobulin (Ig) G is considered the hallmark serologic marker of NMO, its association is not absolute, as NMO IgG is not detected in approximately one-fourth of
Neuromyelitis optica MOG-IgG causes reversible lesions in mouse brain
TLDR
Differences in the results mirror the better outcomes for MOG-IgG compared with AQP4-IGG patients and raise the possibility that Mog-IhG contributes to pathology in some neuromyelitis optica patients.
Histopathology and clinical course of MOG-antibody-associated encephalomyelitis
TLDR
This case contributes a new, so far missing link in the emerging spectrum of MOG‐antibody‐associated encephalomyelitis and antibodies against myelin oligodendrocyte glycoprotein (MOG).
NMO-IgG in the diagnosis of neuromyelitis optica
TLDR
It is shown that a newly detected serum autoantibody (called NMO-IgG) has been reported to distinguish between neuromyelitis optica (NMO) and multiple sclerosis (MS) and this proposal has important clinical implications and therefore demands independent confirmation.
AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance
TLDR
The latest evidence in support of a direct involvement of AQP4-Ab in the immunopathogenesis of NMO is summarized, the diagnostic tests currently available for the detection of this serum reactivity are critically appraised and a strong rationale for the use of therapies targeted against B cells or antibodies in the treatment of N MO is provided.
Mechanisms of Disease: aquaporin-4 antibodies in neuromyelitis optica
TLDR
An antibody-mediated pathogenesis for NMO is supported by several observations, including the characteristics of the AQP4 antibodies, the distinct NMO pathology—which includes IgG and complement deposition and loss of AQP 4 from spinal cord lesions—and emerging evidence of the beneficial effects of B-cell depletion and plasma exchange.
...
...